GLP1R and metabolic dysfunction-associated steatohepatitis: Recently, resmetirom was the first medication approved by the Federal Drug Administration (FDA) specifically for the treatment of adults with non-cirrhotic MASH with moderate to advanced liver fibrosis (5); while several drugs are currently underway in phase III trials for adults with MASH after have demonstrated beneficial effects on both resolution of MASH and improvement of fibrosis, including the GLP-1 receptor agonists semaglutide and survodutide, the PPAR agonist lanifibranor and the FGF21 analog efruxifermin (6–9).